¿Qué ha cambiado en su vida diaria?

Un diagnóstico neurológico puede afectar el movimiento, la sensibilidad, la comunicación, la energía o la independencia de formas muy distintas. Cuéntenos el diagnóstico de su especialista, qué ha cambiado recientemente y las actividades que más quiere proteger.

Comparta el contexto de su diagnóstico.

El resumen de su especialista, su tratamiento actual, la lista de medicamentos y los estudios o informes pertinentes ayudan a nuestro equipo médico a comprender su situación. Si el diagnóstico aún no está claro, díganoslo. Aclararlo u obtener otra opinión especializada puede ser el siguiente paso más útil.

Su diagnóstico

Comparta el diagnóstico exacto o lo que aún no está claro.

Atención actual

Enumere los tratamientos, medicamentos y cambios recientes.

Sus informes

Incluya estudios, informes o el resumen de su especialista.

Inquietudes que nos comparten:

Enfermedad de Parkinson

Un trastorno del movimiento que puede afectar el movimiento, el equilibrio y otras funciones con el tiempo.

Esclerosis múltiple (EM)

Una afección del cerebro y la médula espinal que puede afectar el movimiento, la sensibilidad, la visión y otras funciones.

Accidente cerebrovascular

Una lesión cerebral causada por la interrupción del flujo sanguíneo o una hemorragia; sus efectos varían según la ubicación y gravedad.

Autismo

Una diferencia del neurodesarrollo que puede influir en la comunicación, la experiencia sensorial y los patrones de conducta.

Enfermedad de Alzheimer

Una enfermedad cerebral progresiva que afecta la memoria y el pensamiento.

Esclerosis lateral amiotrófica (ELA)

Una enfermedad progresiva que afecta las células nerviosas que controlan los músculos voluntarios.

Epilepsia

Una afección neurológica que implica una tendencia a presentar convulsiones recurrentes.

Parálisis cerebral

Un grupo de afecciones que afectan el movimiento y la postura y se originan durante el desarrollo cerebral temprano.

Trauma craneoencefálico

Comparta la fecha de la lesión, las imágenes y las evaluaciones de sus especialistas, y los cambios que afectan su memoria, movimiento, comunicación o autonomía diaria.

Lesión de la médula espinal

Cuéntenos el nivel de la lesión, sus capacidades actuales, la rehabilitación que recibe y las metas que desea revisar con el equipo clínico.

Encefalopatía hipóxico-isquémica

Comparta el diagnóstico, los antecedentes médicos desde los primeros años, los informes de especialistas y las metas de apoyo o desarrollo que desea revisar.

Dolor neuropático y neuropatía diabética

Describa el dolor neuropático o la neuropatía diabética, las zonas afectadas, su tratamiento actual y los cambios que más le importan en la vida diaria.

Todos los tratamientos que ofrecemos están respaldados por estudios clínicos.Consulte la investigación

Afecciones neurológicas

141 estudios

Afecciones neurológicas y del desarrollo (118)

The Role of Stem Cell Therapies in the Treatment of Neurodegenerative Diseases. (2024)
Recent advances in stem cell therapy: efficacy, ethics, safety concerns, and future directions focusing on neurodegenerative disorders - a review. (2024)
Perinatal Tissue-Derived Stem Cells: An Emerging Therapeutic Strategy for Challenging Neurodegenerative Diseases. (2024)
Cellular and Noncellular Approaches for Repairing the Damaged Blood-CNS-Barrier in Amyotrophic Lateral Sclerosis. (2024)
Mesenchymal stem cell-derived extracellular vesicles for human diseases. (2024)
The Role of Mesenchymal Stem Cells in Modulating Adaptive Immune Responses in Multiple Sclerosis. (2024)
Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases. (2025)
Blood-brain barrier disruption: a pervasive driver and mechanistic link between traumatic brain injury and Alzheimer's disease. (2025)
Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience. (2023)
Stem cell therapies: a new era in the treatment of multiple sclerosis. (2024)
The evolution of mesenchymal stem cell-derived neural progenitor therapy for Multiple Sclerosis: from concept to clinic. (2024)
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance. (2024)
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis-a systematic review. (2024)
Hematopoietic stem cell transplantation for multiple sclerosis: no inflammation, no response. (2025)
Recent advances in mesenchymal stem cell therapy for multiple sclerosis: clinical applications and challenges. (2025)
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT. (2025)
Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis. (2023)
Stem Cell Transplantation for Multiple Sclerosis: A 2023 Review of Published Studies. (2023)
Unveiling the fate and potential neuroprotective role of neural stem/progenitor cells in multiple sclerosis. (2024)
Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis. (2024)
Hematopoietic stem cell transplantation for multiple sclerosis. (2024)
Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. (2024)
Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study. (2024)
Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial. (2024)
Cerebrospinal fluid mtDNA concentrations are increased in multiple sclerosis and were normalized after intervention with autologous hematopoietic stem cell transplantation. (2024)
The consequences of delayed diagnosis and treatment in persons with multiple sclerosis given autologous hematopoietic stem cell transplantation. (2024)
Evoked potentials after autologous hematopoietic stem cell transplantation for multiple sclerosis. (2024)
Effects of multiple treatments with stem cell therapy in patients with multiple sclerosis. (2024)
Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis. (2025)
Economics of hematopoietic stem cell transplant in immune-mediated neurologic autoimmune diseases. (2024)
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis. (2024)
CELL THERAPY IN ALS: an update on preclinical and clinical studies. (2023)
Long-term survival benefits of intrathecal autologous bone marrow-derived mesenchymal stem cells (Neuronata-R®: lenzumestrocel) treatment in ALS: Propensity-score-matched control, surveillance study. (2023)
Effect of mesenchymal stromal cell transplantation on long-term survival in amyotrophic lateral sclerosis. (2023)
Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis. (2024)
Amyotrophic Lateral Sclerosis: Insights and New Prospects in Disease Pathophysiology, Biomarkers and Therapies. (2024)
Stem Cell Therapy for the Treatment of Amyotrophic Lateral Sclerosis: Comparison of the Efficacy of Mesenchymal Stem Cells, Neural Stem Cells, and Induced Pluripotent Stem Cells. (2024)
Neural Stem/Progenitor Cell Therapy in Patients and Animals with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis. (2025)
Evaluation of Safety and Efficacy of Repeated Mesenchymal Stem Cell Transplantation in Patients with Amyotrophic Lateral Sclerosis (ALS) by Investigating Patient's Specific microRNAs as Novel Biomarkers: A Clinical Trial Study. (2025)
From Diagnosis to Treatment: A Comprehensive Review of Biomarkers and Therapeutic Advances in Parkinson's Disease. (2025)
The neuroprotective effect of human umbilical cord MSCs-derived secretome against α-synuclein aggregates on the blood-brain barrier. (2025)
Pathological mechanisms of neuroimmune response and multitarget disease-modifying therapies of mesenchymal stem cells in Parkinson's disease. (2023)
Mesenchymal stromal cell biotherapy for Parkinson's disease premotor symptoms. (2023)
Phase 1 study of safety and preliminary efficacy of intranasal transplantation of human neural stem cells (ANGE-S003) in Parkinson's disease. (2024)
The prospective role of mesenchymal stem cells in Parkinson's disease. (2024)
Efficacy and efficacy-influencing factors of stem cell transplantation on patients with Parkinson's disease: a systematic review and meta-analysis. (2024)
Stem Cell-Based Approaches in Parkinson's Disease Research. (2024)
Stem Cell Revolutions: An Alliance For Parkinson's Disease Driven By European Commission Consortia. (2024)
Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program. (2024)
Revealing induced pluripotent stem cells' potential as a better alternative to embryonic stem cells for Parkinson's disease treatment based on single-cell RNA-seq. (2024)
Induced pluripotent stem cell-related approaches to generate dopaminergic neurons for Parkinson's disease. (2024)
Stem cells-derived exosomes alleviate neurodegeneration and Alzheimer's pathogenesis by ameliorating neuroinflamation, and regulating the associated molecular pathways. (2023)
Mesenchymal stem cell- and extracellular vesicle-based therapies for Alzheimer's disease: progress, advantages, and challenges. (2023)
miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease. (2023)
Stem Cells as a Novel Source for Regenerative Medicinal Applications in Alzheimer's Disease: An Update. (2024)
Stem cell therapy in Alzheimer's disease: current status and perspectives. (2024)
Non-Drug and Non-Invasive Therapeutic Options in Alzheimer's Disease. (2025)
Intranasal delivery of engineered extracellular vesicles loaded with miR-206-3p antagomir ameliorates Alzheimer's disease phenotypes. (2024)
Advanced nano delivery system for stem cell therapy for Alzheimer's disease. (2024)
Insights on the Characteristics and Therapeutic Potential of Mesenchymal Stem Cell-derived Exosomes for Mitigation of Alzheimer's Disease's Pathogenicity: A Systematic Review. (2024)
An update on stem cell and stem cell-derived extracellular vesicle-based therapy in the management of Alzheimer's disease. (2023)
Recent Advancement in Therapeutic Strategies for Alzheimer's Disease: Insights from Clinical Trials. (2023)
Identification of potential biomarkers related to mesenchymal stem cell response in patients with Alzheimer's disease. (2023)
Mesenchymal Stem Cells Applications in Alzheimer's Disease. (2023)
A systematic review of clinical efficacy and safety of cell-based therapies in Alzheimer's disease. (2024)
Mesenchymal stem cell therapy for Alzheimer's disease: A novel therapeutic approach for neurodegenerative diseases. (2024)
Promoting Alzheimer's disease research and therapy with stem cell technology. (2024)
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial. (2025)
Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy. (2023)
Stem Cells: Recent Developments Redefining Epilepsy Therapy. (2023)
Current state of the epilepsy drug and device pipeline. (2024)
Stem Cell Transplantation Represents a New Strategy for the Treatment of Epilepsy. (2024)
Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial). (2024)
Stem cell therapies for neonatal lung diseases: Are we there yet? Semin Perinatol. (2023)
Development of a new treatment for preterm birth complications using amniotic fluid stem cell therapy. (2023)
The fate and prospects of stem cell therapy in the treatment of hypoxic-ischemic encephalopathy. (2023)
A Pilot Phase I Trial of Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells in Neonates With Hypoxic-Ischemic Encephalopathy. (2023)
Mesenchymal Stromal Cell therapy for Hypoxic Ischemic Encephalopathy: Future directions for combination therapy with hypothermia and/or melatonin. (2024)
Can miRNAs in MSCs-EVs Offer a Potential Treatment for Hypoxic-ischemic Encephalopathy? Stem Cell Rev Rep. (2024)
Bone Marrow Nucleated Cells and Bone Marrow-Derived CD271+ Mesenchymal Stem Cell in Treatment of Encephalopathy and Drug-Resistant Epilepsy. (2024)
Hypoxic-Ischemic Encephalopathy: Pathogenesis and Promising Therapies. (2024)
Efficacy and safety of stem cell therapy in cerebral palsy: A systematic review and meta-analysis. (2022)
The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial. (2022)
Maintenance of the synergistic effects of cord blood cells and erythropoietin combination therapy after additional cord blood infusion in children with cerebral palsy: 1-year open-label extension study of randomized placebo-controlled trial. (2023)
Safety and efficacy outcomes after intranasal administration of neural stem cells in cerebral palsy: a randomized phase 1/2 controlled trial. (2023)
Prospective single center analysis of outcome stem cells transplants in patients with cerebral palsy. (2023)
The Impact of Umbilical Cord Mesenchymal Stem Cells on Motor Function in Children with Cerebral Palsy: Results of a Real-world, Compassionate use Study. (2024)
Cord Blood Treatment for Children With Cerebral Palsy: Individual Participant Data Meta-Analysis. (2025)
Providing holistic care to children with cerebral palsy treated with transnasal neural stem cell transplantation. (2024)
Cell-Based Therapy for Cerebral Palsy: A Puzzle in Progress. (2025)
Cell Therapies for Autism Spectrum Disorder Based on New Pathophysiology: A Review. (2023)
Granulocyte macrophage colony-stimulating factor-induced macrophages of individuals with autism spectrum disorder adversely affect neuronal dendrites through the secretion of pro-inflammatory cytokines. (2024)
Neuroimmune mechanisms in autism etiology - untangling a complex problem using human cellular models. (2024)
Stem Cell Secretions as a Potential Therapeutic Agent for Autism Spectrum Disorder: A Narrative Review. (2024)
Mesenchymal Stem Cells and Purinergic Signaling in Autism Spectrum Disorder: Bridging the Gap between Cell-Based Strategies and Neuro-Immune Modulation. (2024)
Efficacy and Safety of Stem Cell Therapy in Children With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. (2022)
The promise of autologous and allogeneic cellular therapies in the clinical trials of autism spectrum disorder. (2023)
Safety and efficacy of allogeneic umbilical cord blood therapy for global development delay and intellectual disability. (2023)
A snapshot on introspection of autism spectrum disorder. (2024)
Advances in the treatment of autism spectrum disorder: Wharton jelly mesenchymal stem cell transplantation. (2025)
Stem Cell Interventions in Neurology: From Bench to Bedside. (2024)
Potential Mechanism and Perspectives of Mesenchymal Stem Cell Therapy for Ischemic Stroke: A Review. (2024)
Functional implication for myelin regeneration in recovery from ischaemic stroke. (2024)
Advancing stroke therapy: innovative approaches with stem cell-derived extracellular vesicles. (2024)
Extracellular Vesicles Maintain Blood-Brain Barrier Integrity by the Suppression of Caveolin-1/CD147/VEGFR2/MMP Pathway After Ischemic Stroke. (2024)
miRNA in blood-brain barrier repair: role of extracellular vesicles in stroke recovery. (2025)
Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Ischemic Stroke: A Meta-Analysis of Preclinical Studies. (2025)
Clinical state and future directions of stem cell therapy in stroke rehabilitation. (2024)
The Role of Stem Cells as Therapeutics for Ischaemic Stroke. (2024)
Mesenchymal stem cell-derived exosomes: Shaping the next era of stroke treatment. (2023)
Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34 + cells for acute ischemic stroke patients-A randomized, open-label, controlled phase II clinical trial. (2024)
Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis. (2024)
Efficacy and safety of stem cells in the treatment of ischemic stroke: A meta-analysis. (2024)
Therapeutic potential of mesenchymal stem cells for cerebral small vessel disease. (2024)
Safety and Efficacy of Bone Marrow and Adipose Tissue-Derived Mesenchymal Stem Cells for the Treatment of Ischemic Stroke: A Systematic Review. (2024)
Mesenchymal stem cells and their extracellular vesicles as emerging therapeutic tools in the treatment of ischemic stroke. (2024)
Stem Cell-Based Therapies via Different Administration Route for Stroke: A Meta-analysis of Comparative Studies. (2025)
Safety and Efficacy of Stem Cell Therapy in Ischemic Stroke: A Comprehensive Systematic Review and Meta-Analysis. (2025)

Lesiones cerebrales y de la médula espinal (23)

Mesenchymal Stem Cell Therapy in Traumatic Spinal Cord Injury: A Systematic Review. (2023)
Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. (2024)
Traumatic brain injury and stem cell treatments: A review of recent 10 years clinical trials. (2024)
A single intranasal dose of human mesenchymal stem cell-derived extracellular vesicles after traumatic brain injury eases neurogenesis decline, synapse loss, and BDNF-ERK-CREB signaling. (2023)
Safety and efficiency of Wharton's Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study. (2024)
The application of mesenchymal stem cells in the treatment of traumatic brain injury: mechanisms, results, and problems. (2024)
Cell transplantation therapies for spinal cord injury focusing on bone marrow mesenchymal stem cells: Advances and challenges. (2023)
Mesenchymal Stem Cell Transplantation: Neuroprotection and Nerve Regeneration After Spinal Cord Injury. (2023)
Advancing Spinal Cord Injury Treatment through Stem Cell Therapy: A Comprehensive Review of Cell Types, Challenges, and Emerging Technologies in Regenerative Medicine. (2023)
Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Spinal Cord Injury. (2024)
Mesenchymal stem cells and their extracellular vesicle therapy for neurological disorders: traumatic brain injury and beyond. (2025)
Stem Cell-Based Approaches for Spinal Cord Injury: The Promise of iPSCs. (2025)
Research on stem cell therapy for spinal cord injury: a bibliometric and visual analysis from 2018-2023. (2024)
Mesenchymal stem cells in the treatment of spinal cord injury: Mechanisms, current advances and future challenges. (2023)
Intravenous Infusion of Autologous Mesenchymal Stem Cells Expanded in Auto Serum for Chronic Spinal Cord Injury Patients: A Case Series. (2024)
Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial. (2024)
Exosomes Derived from Mesenchymal Stem Cells: Therapeutic Opportunities for Spinal Cord Injury. (2024)
Exosome-mediated repair of spinal cord injury: a promising therapeutic strategy. (2024)
Stem cell therapies for spinal cord injury in humans: A review of recent clinical research. (2025)
Regenerative Medicine Approaches for the Treatment of Spinal Cord Injuries: Progress and Challenges. (2024)
Transplantation of autologous mesenchymal stromal cells in complete cervical spinal cord injury: a pilot study. (2024)
Adverse events of cell therapy clinical trials in human chronic spinal cord injury, a systematic review and meta-analysis. (2024)
Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial. (2024)

La pregunta adecuada. Un plan claro. Un precio claro.

Comparta su diagnóstico y los cambios que afectan su vida diaria. Si nuestro equipo puede ayudarle, su propuesta explicará el tratamiento específico, las citas, el seguimiento, los detalles de la estadía y el precio completo para que pueda considerarla.

Evaluación clínica

Revisamos su diagnóstico, informes y atención actual para confirmar si existe un enfoque pertinente.

Tratamiento definido

Su propuesta identifica el tratamiento, la preparación y las citas propuestas para su situación.

Seguimiento planificado

Las citas de seguimiento y el control de la recuperación se incluyen en su propuesta para que sepa qué esperar.

Un total por escrito

Una propuesta escrita detalla el precio completo del tratamiento. Alojamiento, apoyo y servicios opcionales por separado.

Obtenga una evaluación gratuita